CA-SIRIUS-THERAPEUTICS
2.2.2024 05:01:26 CET | Business Wire | Press release
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kraken Goes Live on Trever to Bring Full-Service Prime Brokerage to European Financial Institutions30.6.2026 10:30:00 CEST | Press release
European banks, brokers and other licensed financial institutions using Trever can now access Kraken Prime’s institutional crypto trading and qualified custody Kraken Prime, the full-service prime brokerage offering trading, qualified custody and other financial services through an integrated platform, is now available through Trever, the operating standard in digital asset banking. Trever’s Digital Asset Operating System is used by financial institutions across Europe to manage the full digital asset lifecycle within a single environment – including trading, treasury, settlement and bookkeeping. From today, banks and brokers using Trever can route execution, settle into qualified custody, record all transactions and access other services through Kraken Prime without leaving their existing operational environment. The integration extends Trever’s connectivity, bringing a prime brokerage relationship into the existing workflows institutional teams use across their digital asset operatio
Microsoft Takes Sisvel Wi-Fi Multimode Patent Pool Licence30.6.2026 10:17:00 CEST | Press release
Microsoft has become a licensee of the Sisvel Wi-Fi Multimode pool. The US computer and software giant is the latest in a string of major companies to take a licence to the standard essential patents offered through the programme. In doing so, it joins ASUS, Hewlett Packard Enterprise and Sony Group Corporation, as well as Huawei, Panasonic, Philips and ZTE which are also pool licensors alongside KPN, Mitsubishi Electric, Orange, Aegis 11 (a Sisvel affiliate), SK Telecom and Wilus. The Sisvel Wi-Fi Multimode pool covers both Wi-Fi 6 and Wi-Fi 7 and offers an efficient way to access essential Wi-Fi rights for years to come. It was publicly launched in January 2026 as the successor to the Sisvel Wi-Fi 6 patent pool. Over a three-year period under that programme, agreements were closed with 40 companies, including Acer, Netgear, Cisco and HP. “It is a pleasure to welcome Microsoft as a licensee of the Sisvel Wi-Fi Multimode pool,” says Alex Debski, Director of Licensing and Counsel Legal
STOKR Secures CASP and PI Licences in Luxembourg Ahead of MiCAR Deadline30.6.2026 10:00:00 CEST | Press release
Authorised by the CSSF just before the 1 July 2026 enforcement deadline, STOKR joins a small group of crypto-asset firms cleared to operate across the EU under a single, harmonised regime. STOKR, the Luxembourg-based digital securities platform, has received authorisation from the Commission de Surveillance du Secteur Financier (CSSF) under the EU's Markets in Crypto-Assets Regulation (MiCAR) and the Law of 10 November 2009 on payment services, securing its Crypto-Asset Service Provider (CASP) and Payment Institution (PI) licences just over a week before MiCAR's 1 July 2026 enforcement deadline. Digital securities fall outside MiCAR's scope but the payment leg does not. To receive, hold, and transfer crypto assets and stablecoins on behalf of clients during subscription and redemption, a platform requires a CASP licence under MiCAR and a PI. Without both, a platform can issue digital securities but cannot move the capital. With MiCAR's transitional period ending on 30 June 2026, a sign
NHOA Energy Awarded Culcairn Battery Contract by Neoen in Australia30.6.2026 09:06:00 CEST | Press release
The landmark Culcairn Battery contract builds on the successful delivery of Neoen’s Blyth Battery by NHOA Energy in Australia, strengthening the long-standing relationship between both companies NHOA Energy, global provider of utility-scale energy storage systems, has been awarded notice-to-proceed by Neoen, one of the world’s leading renewable energy companies, on the latter’s Culcairn Battery, a 215 MW / 963 MWh project to be installed in New South Wales (NSW), Australia. The project will be delivered under an EPC contract in partnership with a joint venture between Equans Solar & Storage and Bouygues Construction Australia and marks a significant new milestone in the long-standing partnership between Neoen and NHOA Energy in Australia. The announcement follows the successful delivery of work by NHOA Energy on Neoen’s 238.5 MW / 477 MWh Blyth Battery in South Australia, in operation since early 2025, and reaffirms NHOA Energy’s leading role in the growth of large-scale energy storage
Manago AI, Formerly SALESmanago, Unveils New Identity and Agentic AI Capabilities to Help Brands Move Faster and Make Powerful Marketing Feel Simple30.6.2026 09:00:00 CEST | Press release
- Manago AI helps brands understand every customer and turn insights into personalised engagement in minutes, dramatically reducing marketing complexity Manago AI today announces the next evolution of its Customer Engagement Platform, combining a new brand identity, agentic AI capabilities, an improved user experience, and a simplified commercial model designed to help growing companies realise value faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630694104/en/ From left: Marcin Stelmach, Director of Customer Success, Klaudia Penkalla, Chief of Staff, Phil Draper, CEO, and Marek Broda, CDFO The launch coincides with the company’s rebrand from SALESmanago, one of the first marketing automation platforms in Europe, to Manago AI. This reflects a broader business transformation focused on helping marketers move faster, reduce complexity and achieve value sooner through AI-powered customer engagement. Designed for eComm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom